Your browser is no longer supported. Please, upgrade your browser.
QURE [NASD]
uniQure N.V.
Index- P/E5.30 EPS (ttm)6.37 Insider Own1.10% Shs Outstand46.04M Perf Week-8.26%
Market Cap1.66B Forward P/E- EPS next Y-1.32 Insider Trans-11.29% Shs Float40.24M Perf Month17.26%
Income303.40M PEG- EPS next Q-1.08 Inst Own94.30% Short Float4.95% Perf Quarter9.15%
Sales500.20M P/S3.31 EPS this Y9.40% Inst Trans5.43% Short Ratio3.45 Perf Half Y15.49%
Book/sh13.76 P/B2.45 EPS next Y-121.00% ROA66.00% Target Price- Perf Year-9.12%
Cash/sh13.81 P/C2.45 EPS next 5Y- ROE91.00% 52W Range25.80 - 52.19 Perf YTD-6.53%
Dividend- P/FCF5.67 EPS past 5Y5.40% ROI-39.00% 52W High-35.29% Beta1.14
Dividend %- Quick Ratio15.10 Sales past 5Y28.80% Gross Margin95.40% 52W Low30.89% ATR1.57
Employees332 Current Ratio15.10 Sales Q/Q336.50% Oper. Margin60.20% RSI (14)50.56 Volatility5.91% 4.25%
OptionableYes Debt/Eq0.11 EPS Q/Q987.90% Profit Margin60.70% Rel Volume0.93 Prev Close33.77
ShortableYes LT Debt/Eq0.11 EarningsJul 26 BMO Payout0.00% Avg Volume578.44K Price33.77
Recom1.70 SMA20-1.14% SMA5010.03% SMA200-0.68% Volume0 Change0.00%
Jun-15-21Initiated BTIG Research Buy $46
May-21-21Initiated UBS Neutral $40
Apr-26-21Resumed Credit Suisse Outperform $78
Apr-01-21Upgrade Mizuho Neutral → Buy $52
Jan-07-21Upgrade Guggenheim Neutral → Buy $62
Nov-24-20Initiated H.C. Wainwright Buy $80
Nov-11-20Initiated Berenberg Buy
Nov-09-20Initiated Jefferies Buy $55
Nov-04-20Initiated Cantor Fitzgerald Overweight $65
Oct-23-20Initiated RBC Capital Mkts Outperform $61
Aug-25-20Initiated Raymond James Strong Buy $75
Jul-31-20Upgrade Robert W. Baird Neutral → Outperform $57
Jun-25-20Downgrade Wells Fargo Overweight → Equal Weight $56
Jun-25-20Downgrade Robert W. Baird Outperform → Neutral $58
Jun-25-20Downgrade Mizuho Buy → Neutral $90 → $61
Dec-03-19Initiated Goldman Buy
Dec-03-19Initiated Cowen Outperform
Nov-05-19Initiated Credit Suisse Outperform
Oct-11-19Initiated Stifel Buy
Sep-25-19Initiated Bernstein Outperform $73
Sep-20-21 02:57PM  
Sep-14-21 10:54AM  
Sep-07-21 07:05AM  
Sep-03-21 06:55PM  
Aug-30-21 07:05AM  
Jul-28-21 07:46AM  
Jul-26-21 08:20AM  
07:05AM  
Jul-22-21 03:03PM  
Jul-13-21 10:10AM  
Jul-02-21 09:00AM  
Jun-23-21 08:27AM  
Jun-22-21 02:49PM  
12:47PM  
11:31AM  
11:31AM  
Jun-16-21 07:05AM  
Jun-10-21 02:26AM  
Jun-02-21 10:31AM  
07:34AM  
May-27-21 11:48AM  
07:05AM  
May-24-21 07:14AM  
May-13-21 07:00AM  
May-10-21 08:25AM  
07:05AM  
May-06-21 07:05AM  
07:00AM  
May-03-21 07:05AM  
Apr-28-21 12:34PM  
07:05AM  
Apr-26-21 04:27PM  
12:03PM  
09:28AM  
08:34AM  
07:05AM  
Apr-08-21 07:05AM  
Apr-07-21 08:22AM  
Apr-05-21 09:54PM  
07:05AM  
Apr-01-21 07:05AM  
Mar-31-21 08:06AM  
Mar-29-21 04:06PM  
03:05PM  
09:26AM  
07:05AM  
Mar-01-21 08:35AM  
07:05AM  
Feb-26-21 07:05AM  
Feb-10-21 05:22AM  
Feb-08-21 04:40PM  
02:03PM  
09:57AM  
07:05AM  
Feb-01-21 07:05AM  
Jan-06-21 10:45PM  
Jan-04-21 11:27PM  
Dec-29-20 08:45PM  
Dec-26-20 04:43PM  
Dec-23-20 11:00AM  
04:20AM  
Dec-21-20 04:40PM  
04:24PM  
10:18AM  
07:55AM  
07:05AM  
Dec-18-20 12:14PM  
Dec-17-20 09:42AM  
Dec-15-20 04:36PM  
Dec-08-20 07:00AM  
Dec-07-20 04:05PM  
Dec-02-20 07:05AM  
Nov-30-20 07:05AM  
Nov-19-20 04:37PM  
09:10AM  
Nov-12-20 11:01AM  
Nov-04-20 10:46AM  
07:05AM  
Oct-29-20 10:55AM  
Oct-27-20 10:25AM  
07:05AM  
Oct-26-20 11:54PM  
03:44PM  
Oct-19-20 12:31PM  
Oct-13-20 07:05AM  
Sep-30-20 07:05AM  
Sep-25-20 07:05AM  
Sep-23-20 10:28AM  
Sep-15-20 09:06AM  
Sep-03-20 07:05AM  
Aug-31-20 10:21PM  
08:56AM  
Aug-26-20 10:44PM  
07:05AM  
Jul-30-20 10:25AM  
07:05AM  
Jul-27-20 12:31PM  
Jul-08-20 12:38PM  
Jun-25-20 08:26AM  
07:54AM  
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gut RobertDirectorSep 21Sale36.614,500164,74537,501Sep 22 09:32 AM
KLEMT CHRISTIANChief Financial OfficerSep 21Sale38.002,40091,20070,783Sep 22 09:24 AM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 21Sale36.712,22981,82766,642Sep 21 03:31 PM
Dolmetsch RicardoPresident, R&DSep 16Sale37.108,603319,17169,126Sep 17 01:19 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 15Option Exercise5.316,00031,86074,871Sep 16 03:06 PM
Kuta Alexander Edward IIIExecutive VP, OperationsSep 15Sale36.326,000217,92068,871Sep 16 03:06 PM
Kapusta Matthew CCEO, CFO, Managing DirectorAug 18Sale28.151,00028,146256,577Aug 20 04:14 PM
Kuta Alexander Edward IIIExecutive VP, OperationsAug 16Option Exercise5.316,00031,86074,871Aug 18 09:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsAug 16Sale28.846,000173,04068,871Aug 18 09:51 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJul 15Option Exercise5.316,00031,86074,871Jul 16 11:11 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJul 15Sale27.226,000163,32068,871Jul 16 11:11 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJul 14Sale27.771,00027,770257,577Jul 21 02:00 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 17Sale35.001,90066,500258,577Jun 21 10:33 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJun 16Sale34.623,450119,453260,477Jun 21 10:33 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJun 15Option Exercise5.316,00031,86074,871Jun 17 11:00 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJun 15Sale35.436,000212,58068,871Jun 17 11:00 AM
Kuta Alexander Edward IIIExecutive VP, OperationsMay 17Option Exercise5.316,00031,86074,871May 18 09:40 AM
Kuta Alexander Edward IIIExecutive VP, OperationsMay 17Sale31.666,000189,96068,871May 18 09:40 AM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 12Sale32.292,25072,652263,927May 14 11:46 AM
Kuta Alexander Edward IIIExecutive VP, OperationsApr 15Option Exercise5.316,00031,86074,871Apr 16 11:55 AM
Kuta Alexander Edward IIIExecutive VP, OperationsApr 15Sale35.066,000210,36068,871Apr 16 11:55 AM
Kapusta Matthew CCEO, CFO, Managing DirectorApr 14Sale35.245,350188,518266,177Apr 22 09:28 AM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 17Sale33.162,25074,617271,527Mar 22 01:11 PM
Kaye JackDirectorMar 02Sale37.6050418,95018,069Mar 04 02:28 PM
Astley-Sparke PhilipDirectorMar 02Sale37.6050418,9509,946Mar 04 02:26 PM
Gut RobertDirectorMar 02Sale36.981,30048,07442,001Mar 04 02:23 PM
Soteropoulos PaulaDirectorMar 02Sale37.6050418,9506,364Mar 04 02:19 PM
Balachandran MadhavanDirectorMar 02Sale37.5050518,9389,945Mar 04 02:10 PM
Meek David D.DirectorMar 02Sale37.5050518,9386,448Mar 04 01:58 PM
Springhorn Jeremy P.DirectorMar 02Sale37.5050518,9389,945Mar 04 01:53 PM
Kuta Alexander Edward IIIExecutive VP, OperationsMar 02Sale37.001,20644,62268,871Mar 04 01:46 PM
KLEMT CHRISTIANChief Accounting OfficerMar 02Sale37.031,35049,99063,604Mar 04 01:43 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 02Sale36.944,974183,740273,777Mar 04 01:39 PM
Kapusta Matthew CCEO, CFO, Managing DirectorFeb 15Sale35.383,800134,452222,938Feb 24 12:46 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 29Sale35.587,000249,049226,738Feb 01 12:04 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale36.0615,750567,901233,738Jan 29 01:53 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale36.0615,750567,901233,738Jan 29 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale37.2015,749585,885249,488Jan 29 01:48 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 27Sale37.2015,749585,885249,488Jan 29 01:53 PM
KLEMT CHRISTIANChief Accounting OfficerJan 27Sale37.387,447278,36948,619Jan 28 10:44 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 27Sale37.234,788178,25751,359Jan 28 10:38 AM
Kuta Alexander Edward IIIExecutive VP, OperationsJan 26Sale39.0171327,81456,147Jan 28 10:38 AM
Gut RobertChief Medical OfficerJan 26Sale39.0960423,61040,919Jan 28 10:49 AM
KLEMT CHRISTIANChief Accounting OfficerJan 26Sale39.0095237,12856,066Jan 28 10:44 AM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 16Option Exercise7.5312,50194,133277,738Dec 21 08:12 AM
Kapusta Matthew CCEO, CFO, Managing DirectorDec 16Sale48.4112,501605,173265,237Dec 21 08:12 AM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 19Option Exercise7.533,12523,531276,592Nov 24 04:25 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 19Sale45.1811,355513,019265,237Nov 24 04:25 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 18Option Exercise7.533,21624,216283,780Nov 20 04:58 PM
Kapusta Matthew CCEO, CFO, Managing DirectorNov 18Sale43.6910,313450,579273,467Nov 20 04:58 PM
Kapusta Matthew CCEO, CFO, Managing DirectorOct 14Sale35.865,250188,256280,564Oct 16 04:10 PM